LY-272,015

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Addbot (talk | contribs) at 20:44, 19 March 2013 (Bot: Migrating 1 interwiki links, now provided by Wikidata on d:q6460411). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

LY-272,015
Clinical data
Other namesLY-272,015; 1-[(3,4-Dimethoxyphenyl)methy]-2,3,4,9-tetrahydro-6-methyl-1H-pyrido[3,4-b]indole
Identifiers
  • 1-(3,4-dimethoxybenzyl)-6-methyl-2,3,4,9-tetrahydro-1H-β-carboline
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H24N2O2
Molar mass336.426 g/mol g·mol−1
3D model (JSmol)
  • c4cc(C)cc3c4nc2c3CCNC2Cc(cc1OC)ccc1OC
  (verify)

LY-272,015 is a beta-carboline derivative drug developed by Eli Lilly, which acts as a potent and selective antagonist at the serotonin 5-HT2B receptor. It has anti-hypertensive effects in animal models,[1][2] and is also used in research into the other functions of the 5-HT2B receptor.[3]


References

  1. ^ Watts SW, Fink GD. 5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats. American Journal of Physiology. 1999 Mar;276(3 Pt 2):H944-52. PMID 10070078
  2. ^ Russell A, Banes A, Berlin H, Fink GD, Watts SW. 5-Hydroxytryptamine(2B) receptor function is enhanced in the N(omega)-nitro-L-arginine hypertensive rat. Journal of Pharmacology and Experimental Therapeutics. 2002 Oct;303(1):179-87. PMID 12235249
  3. ^ Günther S, Maroteaux L, Schwarzacher SW. Endogenous 5-HT2B receptor activation regulates neonatal respiratory activity in vitro. Journal of Neurobiology. 2006 Aug;66(9):949-61. doi:10.1002/neu.20253 PMID 16758492


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=LY-272,015&oldid=545511551"